Posted by Michael Wonder on 21 Feb 2022
Bayer’s new treatment Kerendia (finerenone) approved in EU for adult patients with chronic kidney disease associated with type 2 diabetes
21 February 2022 - Kerendia is the first non-steroidal, selective mineralocorticoid receptor antagonist to demonstrate positive kidney and cardiovascular outcomes in patients with chronic kidney disease associated with type 2 diabetes.
The European Commission has granted marketing authorisation in the European Union for finerenone under the brand name Kerendia.
